Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase
December 15, 2025
Presentations
Medical Digest SITC Interview – Phase I Trial of DOC1021 Cell-Based Immunotherapy for Resectable or Borderline Resectable Ductal Adenocarcinoma
November 27, 2025
Diakonos Oncology Presents Promising Phase I Results of Dubodencel (DOC1021) at the ASCO 2025 Annual Meeting
June 2, 2025
Diakonos Oncology Presents Phase I Analysis of DOC1021 at the 2025 American Academy of Neurology Annual Meeting
April 9, 2025
2025 Spring Symposium hosted by the William T. Shearer Center for Human Immunobiology
March 7, 2025
6th Annual Glioblastoma Drug Development Summit
February 19, 2025
SNO 2024 Presentation: DOC1021 Cell-Based Vaccination as Adjuvant Therapy for Glioblastoma: Phase I Clinical Trial Analysis
November 22, 2024
SITC 2024 Poster: Vaccination by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Correlation of Immune Response and Early Efficacy Signal with Vaccine Cell Gene Signature
November 9, 2024
CNS 2024 Presentation: Vaccination by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Analysis of Phase I Results
September 30, 2024
AACR 2024 Poster: Vaccine Immunotherapy by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Ongoing Phase 1 Analysis
April 9, 2024
Connect with us on social
